Headache
| Migraine
Headache
Migraine

Pooled Analysis of Cardiovascular Safety with Fremanezumab Treatment in Patients with Migraine by Number of Cardiovascular or Cerebrovascular Risk Factors

Tim P. Jürgens, MD, PhD

AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW

import_contacts 7 min
headphones 4 min

In this medfyle

Expert commentary by Morris Levin, MD

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Acknowledgements
Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:

Tim P. Jürgens, MD, PhD
Head of Headache Center North-East
Dept. of Neurology, Headache Center North-East, University Medical Center of Rostock
Rostock, Mecklenburg-Vorpommern, Germany

The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Morris Levin, MD
UCSF Department of Neurology

About the Expert
Read more arrow_downward Hide arrow_upward

Morris Levin, MD
UCSF Department of Neurology

Dr Levin is Professor of Neurology at the University of California, San Francisco, where he directs the UCSF Headache Center.  He is also actively involved in research and teaching activities at UCSF.  He is board certified in Neurology with special qualification in Pain Medicine (ABPN).  Dr Levin is also board certified in Headache Medicine (UCNS).

Dr Levin authored a number of medical journal articles and textbook chapters in the areas of headache and pain.  He is the author of Neurology Clinical Case Studies (Anadem 2003), Comprehensive Review of Headache Medicine (Oxford University Press 2008) and Emergency Neurology (Oxford University Press 2013). He is the co-author of Head, Neck and Facial Pain (Anadem 2006), Educational Review Manual in Neurology (Castle Connolly 2006), Headache and Facial Pain (Oxford University Press 2009) and Refractory Migraine (Oxford University Press 2010). He is also the co-author of “Understanding Your Migraines” (Oxford University Press 2017), written primarily for patients and families.

He is an active member of the American Headache Society, where he is on the Board of Directors, and the International Headache Society, where he is chair of the Ethics Committee. He is also a member of the HCOP Board of directors.  He is a Fellow of the AAN, AHS and ANA.

Particular academic interests of Dr Levin include Secondary Headaches, Professional Medical Ethics, and Education in Neurology, Headache Medicine and Pain Medicine. 

References
Read more arrow_downward Hide arrow_upward

1. MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. Wiping Out CGRP: Potential Cardiovascular Risks. Trends in Pharmacological Sciences 2016;37:779-788.

2. Favoni V, Giani L, Al-Hassany L, et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? The Journal of Headache and Pain 2019;20(1):27.

3. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. The New England Journal of Medicine 2017;377:2113-2122.

4. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 2018;319:1999-2008.

5. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019;394:1030-1040.


Feedback